Politics / Law

Heard in Brussels – A brave new world for 2020?

04.11.2010

Brussels – The European Commission has finally published its long-awaited ‘2020 Flagship Initiative’ to build an ‘Innovation Union’. The report examines at where Europe is now and sets targets for the upcoming decade. Let's take a look at what impact it will have on biotech. The report starts with a frank admission of where Europe’s weaknesses lie and what member states and the European Commission must achieve. It is refreshingly open, recognising that strength of university research is not enough to compete globally on an economic level, and that the whole value chain needs improving.
The good news is that SMEs, SMEs, SMEs seem to be order of the day – with the recognition that Europe’s SMEs still face many hurdles delivering on their economic potential. It's clear that we won’t build a European Genzyme with the current structure. So what does the Commission intend to do in this ‘Son of Lisbon’? Ten years is not all that long, and bearing in mind that 2010 is nearly over, we had better get on with it!
European Innovation Partnerships are the first activity out of the bloc, with a focus on active and health ageing – that's good news for biotechnology here. Coordinating national investment, fast tracking regulation and more critical mass in procurement are very attractive and have long been called for. But can Europe really overcome national differences to help European technology get to market?
A nice touch is the launch of an independent university ranking system. It's a laudable goal, as long as it's truly independent and not based on the opinions of the universities themselves about their general brilliance. Another self-assessment exercise that excuses weak technology scouting, maturation and transfer will not be welcomed by those involved in commercial biotech. Research funding of course gets a mention, and companies can take heart from the increasing momentum towards SME-driven projects. FP7 Health has already made a good start here with two-stage proposals, and there is much more to be done. There's plenty of evidence of the importance of SMEs in funding research, and we look forward to a scale-up of existing efforts.
Private investment also comes under scrutiny, with a slightly optimistic statement about the current success of additional tools for biotech SMEs. Plans to open up cross-border investment are welcome, but Europe needs to extend support to earlier-stage SMEs to make it more favourable for US investment as well.
The elusive EU patent has been given a deadline of 2014, when the first of those wondrous documents will be issued. So dear reader – can we expect the fighting over words in Spanish/Calatan/French/Outer Mongolian to be resolved soon?
So there you have it. All in all, a well-intentioned framework for the next 9 years. We say ‘let’s do it’ and ‘get tough European Commission’. But turning ideas into actions requires a strong hand with an eye on the 2020 prize rather than the opinions of tomorrow.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/heard-in-brussels-a-brave-new-world-for-2020.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK71.7%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.3%
  • IMMUNICUM AB (S)16.60 SEK-36.2%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP756.4%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper